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Abstract
The immune system spontaneously responds to tumor-associated antigens in peripheral blood of
colorectal cancer (CRC) patients. Regulatory T cells (Treg) are suspected of influencing the
interaction between the tumor and immune system and thus the course of malignant diseases.
However, the function of Tregs in the development of T cell responses and on the clinical course
of CRC is not clear. We analyzed Treg infiltration (FOXP3 staining) in situ in 40 CRC patients and
investigated whether there is a correlation to disease stage, systemic T cell response, and survival.
Treg infiltration was significantly higher in CRC than in healthy colon. Stromal Treg infiltration was
significantly higher than epithelial infiltration in CRC. Furthermore, Treg infiltration in the tumor
was significantly higher in limited disease than in metastatic CRC. The average Treg infiltration rate
in the tumor was non-significantly higher in patients without systemic TAA-specific T cell response.
Survival did not differ between patients with high Treg infiltration and those with low Treg
infiltration. In conclusion, a direct link between Treg infiltration in the tumor and the development
of a systemic T cell response in CRC cannot be proven. However, local Treg infiltration was
significantly higher in limited disease, in which a systemic TAA-directed T cell responses is less
frequently observed.
Background
In the last years, immunotherapy of malignant diseases
and the understanding of underlying mechanisms have
made rapid progress despite limited clinical response [1].
T cells directed against tumor antigens are believed to play
a crucial role in mediating anti-tumor effects. Even with-
out prior immunotherapy, spontaneous T cell responses
against tumor antigens have been described in a variety of
malignant diseases [2]. Colorectal cancer (CRC) has been
intensely studied for interactions with the immune sys-
tem. Although the colon is considered a rather tolerogenic
organ, spontaneous T cell responses against several
tumor-associated antigens (TAA) have been detected in
the peripheral blood of CRC patients, particularly in met-
astatic disease [3,4]. However, patients with peripheral
TAA-directed T cell response showed no benefit in a first
survival analysis with a limited number of CRC patients
[5]. Interestingly, active specific immunotherapy of meta-
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static CRC only causes a clinical response in less than 1%
of patients despite the successful induction of immuno-
logical responses [6]. Multiple factors like the immune
system, tumor stroma, and tumor cells influence the
induction and modulation of tumor-directed immune
responses [7]. Limited anti-tumor activity of antigen-spe-
cific T cells at a clinical level may be limited in CRC
patients for various reasons. One major reason for the
clinical failure of tumor-directed immune responses
might be the immunosuppressive effect of tumor-infiltrat-
ing regulatory T cells.
The immune system is potentially able to develop
immune responses against self antigens and tumor-associ-
ated antigens. Regulatory T cells (Tregs) play a crucial role
in regulating the balance between the attack and tolerance
of such antigens. Regulatory CD4+ CD25+ FOXP3+ T cells
are a subset of T cells mediating immunological tolerance
by suppressing the activation of autoreactive T cells. Tregs
not only inhibit the development of autoimmune-medi-
ated diseases such as inflammatory bowel disease or intes-
tinal graft-versus-host disease [8,9] but are also suspected
of impeding immunosurveillance against autologous
tumor cells [10]. Tregs have been found to be increased in
the peripheral blood of patients suffering from various
malignant diseases. Wolf et al. reported an increase of
Tregs in peripheral blood of patients with epithelial
malignancies [11]. Sasada et al. [12] described an
increased percentage of Tregs among lymphocytes in
peripheral blood of patients with gastrointestinal cancers.
An increase of Tregs in peripheral blood has also been
reported for hepatocellular cancer and non-small cell lung
cancer [13,14]. Kono et al. [15] found higher Tregs in
patients with advanced gastric and esophageal cancer than
in those with limited disease. Ichihara et al. [16] reported
an increase of Tregs not only in the peripheral blood of
patients with gastric and esophageal cancer but also in the
tumor itself compared to healthy mucosa. Moreover, they
demonstrated a higher Treg infiltration in advanced gas-
tric/esophageal cancer [16]. All of this suggests a role of
Tregs in tumor development, which may be related to
immunosuppression in humans.
Several mouse studies have shown that depletion of regu-
latory T cells improves anti-tumor immunity [17-19]. For
example, Ko et al. [20] found FOXP3+CD25+CD4+ Tregs
predominantly in growing tumors in mice that had not
received an agonistic monoclonal antibody against gluco-
corticoid-induced tumor necrosis factor receptor family-
related protein (GITR), thus suggesting that tumor-infil-
trating natural Tregs may hamper effective tumor immu-
nity. A similar conclusion can be drawn from the work of
Turk et al. [21], which shows that melanomas were immu-
nologically rejected after Treg inhibition, and an improve-
ment of anti-tumor T cell response was obtained when
Tregs had been depleted before immunization of mice. In
a murine colon cancer model, Ghiringelli et al. [22] dem-
onstrated that Tregs suppress anti-tumor immunity and
that this effect can be circumvented when Tregs are
depleted by cyclophosphamide. This stimulated intensi-
fied research on the interaction between Tregs and adop-
tive CD8+ T cell transfer. Antony et al. [23] described a
reduced effect of adoptively transferred tumor-antigen-
directed CD8+ T cells when given together with Tregs in
mice. Interestingly the in vitro induction of tumor-anti-
gen-specific (anti-NY-ESO-1) antibodies required Treg
depletion from seronegative cancer patients and healthy
donors [24]. This is in accordance with data by Rosenberg
& Dudley [25], which suggest that Treg depletion may also
be a prerequisite for a clinically effective adoptive T cell
transfer in humans.
As mentioned above, Tregs are suspected of reducing T cell
activity, but their role in the development of tumor-anti-
gen-specific T cell responses has not yet been investigated
in detail. Furthermore, it is not known whether the intra-
tumoral presence of Tregs has an impact on the antigen-
specific T cell response, clinical course, and survival of
CRC patients. With regard to tumors of other organs,
Albers et al. [26] described an increased number of regu-
latory and antigen-specific T cells in head and neck cancer.
Yu et al. [27] observed Treg accumulation at the tumor
site. They were able to show in a murine fibrosarcoma
model that Treg inhibition resulted in a changed cytokine
milieu in the tumor and an eradication of tumors. Viguier
et al. (28) reported that the number of FOXP3 expressing
regulatory T cells is increased in human metastatic
melanoma lymph nodes. These cells inhibited in vitro pro-
liferation and cytokine production of CD8 +T cells [28]. It
was shown for ovarian cancer that tumoral Tregs suppress
tumor-specific T cell immunity and contribute to reduced
survival [29]. Another study on ovarian cancer patients
found that not only intraepithelial CD8+ tumor-infiltrat-
ing lymphocytes but also a high CD8+/CD25+FOXP3+
regulatory T cell ratio (i.e., low relative FOXP3 infiltra-
tion) is associated with a favorable prognosis [30]. More-
over, Wolf et al. [31] reported that a high expression level
of FOXP3 in ovarian cancer is associated with a poorer
prognosis. Briefly, the latter three studies suggest that high
Treg infiltration is associated with a poorer prognosis in
ovarian cancer. Overall, targeting Tregs may have an
important impact on immunotherapeutic anti-cancer
strategies and the clinical outcome of cancer patients [19].
The aim of our study was to analyze the infiltration of
CRC by FOXP3-positive Tregs in situ and to investigate
whether there is a correlation to disease stage, systemic
TAA-specific T cell response, and survival of CRC patients.
We applied an immunohistochemical double labeling
method using anti-FOXP3-Ab and anti-CD3-Ab; and sinceJournal of Translational Medicine 2006, 4:52 http://www.translational-medicine.com/content/4/1/52
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CD8+ T cell infiltration has been described as a positive
prognostic factor in CRC [32-37], we additionally exam-
ined CD8 T cell infiltration in relation to Treg frequency,
disease stage and survival.
Materials and methods
Patient selection and T cell assays
After receiving institutional review board approval and
informed consent, we collected and froze peripheral
blood mononuclear cells from CRC patients for T cell
analysis. All analyses were performed in compliance with
the Helsinki Declaration. HLA-A2-positive patients had
been tested for the presence of T cell responses against the
HLA-A*0201 presented T cell epitopes Ep-CAM p263-
271, her-2/neu p654-662, and CEA p571-579 by ELISPOT
assay. These T cell responses have been previously
reported in more detail; and HLA analysis and ELISPOT
were performed as previously described [3,4]. Positive T
cell responses were also defined as described elsewhere [3-
5]. Inclusion criteria were sufficient tumor sections for
immunohistochemistry and sufficient clinical data. As a
control group, we have analyzed biopsies from 12 healthy
donors who underwent colonoscopy for CRC screening.
Immunohistochemistry
Immunostaining was performed according to a previously
published protocol with slight modifications [38]. Briefly,
4 μm-thick serial sections were cut, deparaffinized and
subjected to a heat-induced epitope retrieval step before
incubation with antibodies. Sections were immersed in
sodium citrate buffer solutions at pH 6.0 and heated in a
high-pressure cooker. The slides were incubated with the
monoclonal antibody against CD8 purchased from Dako,
Glostrup, Denmark (clone C8/144B, dilution 1:100). The
alkaline phosphatase anti-alkaline phosphatase complex
(APAAP) method was used for detection. Alkaline phos-
phatase was revealed by Fast Red as chromogen. For dou-
ble immunoenzymatic labeling of FOXP3/CD3, slides
were blocked using a peroxidase blocking reagent (Dako)
and incubated for 30 minutes with the rat monoclonal
antibody against the amino terminus of the human
FOXP3 protein (PCH101, 1:500; eBioscience, San Diego,
USA), followed by biotin-conjugated rabbit anti-rat
(Dako, 1:200) and the EnVision peroxidase kit (Dako).
Sections were then incubated for 30 minutes with the sec-
ond antibody against CD3 (clone UCHT1, 1:25, Dako)
and visualized by the APAAP method. Tonsillar tissue
with follicular hyperplasia served as a positive control dis-
playing scattered T cells in the interfollicular area with
nuclear expression of FOXP3. Negative controls were per-
formed by omitting primary antibodies. Ten randomly
selected high power fields (1 HPF = 0,237 mm2) were ana-
lyzed for T cell infiltration in both the epithelium and
stroma/lamina propria, and 10 HPF were averaged in each
case.
Statistical and survival analysis
Treg infiltration and systemic T cell response
Tregs were either analyzed separately as epithelial or stro-
mal infiltration or as the sum of both as total Treg infiltra-
tion. The local Treg infiltration of patients with and
without CRC was compared using a two-sided Student's t-
test. Epithelial and stromal Treg infiltration in CRC was
also compared using a two-sided Student's t-test. For the
respective further analyses, CRC patients were grouped
according to their positive or negative peripheral T cell
response.
T cell (Treg, CD3, CD8) infiltration and survival
All patients were grouped according to their T cell infiltra-
tion. The median was used to separate patients with high
infiltration from those with low infiltration. A Kaplan-
Meier analysis was performed to compare survival of
patients with high and low infiltration. Statistical signifi-
cance was determined by the log rank test. All calculations
for CD8 infiltration are descriptive post-hoc analyses,
since Treg infiltration was the primary endpoint of our
study. The association between Treg/CD8 ratio and sur-
vival was calculated in this way.
Stage correction
To reduce the influence of disease stage as prognostic fac-
tors, we grouped patients according to their disease stage.
Stage correction was performed by categorizing patients
according to their UICC stage. UICC I and II were com-
bined because only one patient was UICC I. These stage-
grouped patients were sorted according to their respective
T cell infiltration. The median was used again to separate
patients into low and high infiltration groups. All patients
with low infiltration of stage group I+II, III, and IV were
combined to make a new "stage-corrected low infiltration
group". The same was done for a "stage-corrected high
infiltration group". These two groups were then compared
using Kaplan-Meier survival analysis. Statistical signifi-
cance was determined by the log rank test.
Association between T cell infiltration, stage, age and gender and the 
correlation between Treg and CD8 infiltration
To analyze differences between T cell infiltration and
stage, patients were grouped according to limited (UICC I
and II) and metastatic (UICC III and IV) disease. These
two groups were compared for tumoral and stromal infil-
tration by Tregs and CD8 T cells using the Student's t-test.
A correlation (Pearson) was calculated for Treg and CD8
infiltration for both stromal and epithelial tumor infiltra-
tion. Moreover, we tested the association between T cell
infiltration and age (Pearson correlation) and gender (t-
test).
P < 0.05 was considered significant and p ≤ 0.1 a trend.
SPSS software was used. All analyses other than Treg infil-Journal of Translational Medicine 2006, 4:52 http://www.translational-medicine.com/content/4/1/52
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tration/disease stage, Treg infiltration/systemic T cell
response and Treg infiltration/survival are descriptive
because they represent post hoc analyses.
Results
Patient characteristics
Forty CRC patients met all inclusion criteria. One patient
had UICC I, 20 patients UICC II, six patients UICC III, and
13 patients UICC IV. Eleven patients tested positively for
a systemic TAA-specific T cell response to HLA-A2-binding
peptides of CEA, Ep-CAM, and/or her-2/neu. Twenty-one
patients were female and nineteen male. Mean age at first
diagnosis was 62.1 years (patients with T cell response:
61.7 years, patients without T cell response: 62.2 years).
As a control, we analyzed the colon biopsies of twelve
healthy donors who underwent screening colonoscopy
without evidence for CRC. Mean age of these donors was
64.6 years, (7 males, 5 females). See also table 1.
Treg infiltration in CRC and normal colon
Treg infiltration was found in all 40 CRC samples. The
mean total Treg infiltration in CRC was 12.9/HPF while in
healthy colon tissue a mean total Treg infiltration of 0.6/
HPF was found. This difference was highly significant (p <
0.01). See also table 1.
Treg infiltration in stroma and epithelium
The stromal Treg infiltration (mean 10.8/HPF) was signif-
icantly higher than the epithelial Treg infiltration (2.0/
HPF) in CRC (p < 0.01). In healthy controls, we found a
mean of 0.1 Tregs/HPF in the epithelium and 0.6 Tregs/
HPF in the lamina propria of healthy donors. For both the
epithelium and stroma/lamina propria, Treg infiltration
was significantly higher (p < 0.01) in the tumor than in
healthy colon. Representative samples are given in figure
1.
Treg infiltration and CRC stage
Total Treg infiltration was significantly higher in limited
disease than in metastatic CRC (17.8/HPF vs. 9.9/HPF, p
= 0.04). This difference was mainly based upon infiltra-
tion pattern in stroma (15.8/HPF vs. 7.8/HPF; p = 0.03).
Treg infiltration and systemic T cell response in CRC
The mean total Treg infiltration in patients without TAA-
specific T cell response was 14.1/HPF, in patients with a
TAA-specific T cell response 9.6/HPF. This difference,
however, did not reach significant level (p = 0.16). In both
tumor epithelium and stroma, the average Treg infiltra-
tion rate was slightly higher in patients without systemic
TAA-specific T cell response, but these differences were
also not significant. For stromal infiltration, patients with
a systemic T cell response had a mean of 7.3 Tregs/HPF
and patients without T cell response 12.2 Tregs/HPF (p =
0.11). The two patients in the limited stage of disease with
a positive T cell response had a mean Treg epithelial infil-
tration of 2.0/HPF and a stromal infiltration of 8.7/HPF.
The epithelial infiltration is similar to that of patients with
limited disease and without T cell response; patients with-
out T cell response in limited stages of disease had higher
Treg stromal infiltration (14.1/HPF, significance not
tested due to low patient number). The infiltration rates in
metastatic disease – independent of stage – were similar to
the two patients with limited disease and T cell response.
Treg infiltration and survival in CRC
There was no difference in survival between patients with
high total Treg infiltration and those with low total Treg
infiltration, neither with nor without correction for the
stage of CRC. In a descriptive post-hoc subset analysis a
weakly better survival was found for patients with higher
epithelial Treg infiltration after stage correction (p = 0.04).
CD8 T cell infiltration in CRC and normal colon
CD8 infiltration was found in all CRC and healthy colon
samples. Total CD8 T cell infiltration was significantly
higher in CRC (28.5/HPF) than in healthy colon tissue
(11.3/HPF, p = 0.03). While the CD8 infiltration of epi-
thelial tissue was not significantly different between
healthy colon (7.9/HPF) and CRC (9.5/HPF), stromal
Table 1: FOXP3 infiltration
n FOXP3/HPF ± SD P value
Healthy controls 12 0.6 ± 0.3
Mean age 64.6 years, 5 female, 7 male
< 0.01
CRC 40 12.9 ± 9.1
Mean age 62.1 years, 21 female, 19 male
Stromal 40 10.8 ± 8.4 < 0.01
Epithelial 40 2.0 ± 2.2
Limited (UICC I+II) 21 17.8 ± 10.6 0.04
Metastatic (UICC III+IV) 19 9.9 ± 6.1
Positive T cell response 11 9.6 ± 7.3 0.16
Negative T cell response 29 14.1 ± 9.5Journal of Translational Medicine 2006, 4:52 http://www.translational-medicine.com/content/4/1/52
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CD8 infiltration was significantly higher in CRC (19.0)
than in the lamina propria of healthy colon (3.4/HPF, p <
0.01). Furthermore, in healthy tissue, epithelial CD8 T cell
infiltration was significantly higher than infiltration of the
lamina propria (p < 0.01). In contrast, in CRC, CD8 T cell
infiltration was significantly higher in the stroma than in
the epithelium (p < 0.01).
CD8 T cell infiltration of CRC and Treg infiltration, stage 
and survival in CRC and
There was a weak positive correlation between Treg and
CD8 (Pearson 0.625, p < 0.01) infiltration in the epithe-
lium. No correlation was found between stromal Treg and
CD8 infiltration (Pearson 0.273, n.s.). In all analyses,
higher CD8 infiltration was associated with better sur-
vival. However, these data were not significant. There was
only a statistical trend for better survival in patients with
higher CD8 infiltration for stromal CD8 infiltration with-
out stage correction (p = 0.06). There was a trend toward
higher epithelial CD8 infiltration in the limited stage of
CRC than in metastatic disease (p = 0.10). Stromal CD8
infiltration was increased in patients with limited CRC at
a non-significant level (p = 0.33).
Treg/CD8 ratio and survival in CRC; and age, gender and T 
cell infiltration of CRC
Since prior studies have analyzed ratios between Tregs and
CD8 T cells in relation to survival, we also calculated the
Immunohistochemical labeling of CD8+ and CD3+/FOXP3+ T cells of representative colon cancer specimens with one case  demonstrating a high number of CD8+ T cells (A) and CD3+ T cells (red, membranous) with a high proportion of regulatory T  cells co-expressing FOXP3 (brown, nuclear) in the stroma (C) and the malignant epithelium of the tumor (inset) and another  case with a low number of CD8+ T cells (B) and only a few CD3+ T cells and FOXP3+ Treg (D) Figure 1
Immunohistochemical labeling of CD8+ and CD3+/FOXP3+ T cells of representative colon cancer specimens with one case 
demonstrating a high number of CD8+ T cells (A) and CD3+ T cells (red, membranous) with a high proportion of regulatory T 
cells co-expressing FOXP3 (brown, nuclear) in the stroma (C) and the malignant epithelium of the tumor (inset) and another 
case with a low number of CD8+ T cells (B) and only a few CD3+ T cells and FOXP3+ Treg (D).Journal of Translational Medicine 2006, 4:52 http://www.translational-medicine.com/content/4/1/52
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association of the Treg/CD8 ratio with survival. There was
no association between higher or lower Treg/CD8 ratio
and improved survival. No correlation was found between
infiltration of tested T cell subpopulations (CD3, CD8,
Treg) and age or gender.
Discussion
Transcription factor forkhead box P3 (FOXP3) is a key
intracellular marker and an important developmental and
functional factor for CD4+ CD25+ regulatory T cells [39-
41]. FOXP3 fulfills the criteria of a Treg-specific marker,
which is, at least in differentiated Treg, not known to be
substantially regulated and represents a good marker for
quantifying Treg in tissues [31]. Here, we used FOXP3
staining in CRC to analyze Treg infiltration of CRC in situ
and to test whether there is a correlation to a disease stage,
systemic TAA-specific T cell response, and survival of CRC
patients.
Tregs infiltrated all 40 CRC samples with higher Treg fre-
quency in the stroma than in the tumor epithelium. In
agreement with prior studies in various malignant dis-
eases [16,26-28], we found significantly higher numbers
of Tregs in CRC than in normal colon tissue. Although
counts differ from patient to patient and, in particular, are
relatively low in the epithelium, we found an approxi-
mately 20-fold increase of infiltrating Tregs in CRC com-
pared to healthy colon.
Increased regulatory T cells in peripheral blood have been
associated with advanced gastrointestinal tumor [15].
Interestingly, we found an approximately 2-fold increase
of Tregs at the tumor site in CRC patients with limited
compared to metastatic disease (p < 0.05). This difference
is mainly based on a higher stromal Treg infiltration in
limited CRC. The reason for this observation is unknown.
However, it underlines the importance of in situ analyses.
We speculate that migration of Tregs away from the pri-
mary tumor site during metastatic spread might be impor-
tant in this setting, which would explain the Treg increase
in peripheral blood as described by others. Furthermore,
our data show that local Treg infiltration in malignant dis-
ease may be a dynamic process, with increased numbers
as an initial response in limited disease followed by a rel-
ative decrease after metastatic spread.
In CRC, the average Treg infiltration rate was slightly
higher in patients without systemic TAA-specific T cell
response. Although these differences were not significant,
this may be a first indication of a T cell response-suppress-
ing role of tumor-infiltrating Tregs in CRC. In this context,
the above described increased Treg infiltration in limited
disease is particularly interesting because systemic T cell
responses have been detected significantly less often in
patients with limited disease (3, 4). This might suggest an
indirect interaction between systemic T cell response and
Treg infiltration. Of note, the herein presented T cell
responses against the TAA EpCAM, her-2/neu, and CEA
represent only a small proportion of potential T cell tar-
gets in CRC.
Evaluating a possible interaction between Treg infiltration
and survival required a stage-corrected analysis due to the
stage-dependency of survival and Treg infiltration. No
association was found between total Treg infiltration and
survival neither with nor without stage correction. In a
descriptive post-hoc analysis a weakly better survival was
found for patients with higher epithelial Treg infiltration
after stage correction. This subset analysis must not be
over-interpreted and must be seen with great caution
because of multiple testing and the low number of epithe-
lial Treg in CRC. Nonetheless, assuming that high Treg
infiltration reduces anti-tumor immunity and thus sur-
vival, our results may seem surprising at first glance; and,
e.g., in ovarian cancer, high Treg infiltration seems to be
an adverse prognostic factor [29-31]. However, contrast-
ing results are reported for various neoplasms. Erdman et
al. [42] have shown that adoptive transfer of Tregs into
mice significantly inhibited the development of microbi-
ally induced colon carcinoma. In a study on human
Hodgkin lymphoma, it was shown that low FOXP3+ cell
numbers correlated with negative clinical outcome [43].
Additionally, a recent study demonstrated that high num-
bers of tumor infiltrating FOXP3-positive regulatory T
cells are associated with improved survival in follicular
lymphoma [44]. It is possible that in some malignant dis-
ease – so far preferentially lymphoproliferative or bacte-
ria-induced diseases – infiltrating Tregs may have a
protective effect by reducing/delaying the development of
an aggressive and cytotoxic, potentially proliferogenic
cytokine milieu, which is the basis for the inflammation-
driven progress of malignant diseases [45,46]. In accord-
ance with our study, Pages et al. [47] measured FOXP3 at
the RNA level in CRC and found no difference in survival
comparing high and low expression.
Since CD8+ T cell tumor infiltration has been described as
a positive prognostic factor in CRC [32-37], we performed
an analysis of CD8 T cell infiltration in relation to disease
stage and survival. First, based on our in situ approach, it
was interesting to see that the increased CD8 infiltration
in CRC compared to healthy colon was based on
increased stromal CD8 tumor infiltration. Furthermore,
we found a reversion of CD8 T cell distribution from
higher epithelial CD8 infiltration in healthy colon to
higher stromal CD8 infiltration in CRC suggesting a CD8
T cell shift to the stroma during tumor development. In
accordance with the above mentioned previous studies,
we found a trend for better survival in CRC patients with
higher stromal CD8 infiltration. This may be due to anJournal of Translational Medicine 2006, 4:52 http://www.translational-medicine.com/content/4/1/52
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increase of CD8 infiltration in limited disease compared
to metastatic disease as we found in our study. Thus, for
further analyses on the influence of CD8 infiltration of
CRC, it has to be taken into account that CD8 infiltration
may be higher in the limited stages of the disease. Since
ratios between Tregs and CD8 T cells in relation to sur-
vival were used in a prior study in ovarian cancer [30], we
analyzed the association of the Treg/CD8 ratio with sur-
vival. No correlation was found. This difference between
findings in ovarian cancer and CRC may be due to specific
biological characteristics of each tumor type during pro-
gression with predominantly local spread in ovarian can-
cer and a higher tendency for systemic metastasis (e.g. to
the liver) in CRC. While no correlation was found
between stromal Tregs and CD8 infiltration in our study,
it was interesting to see that Tregs and CD8 infiltration
weakly correlated in the epithelial tissue.
Regulatory T cells are seen as a hindrance for clinically suc-
cessful tumor-directed T cell responses particularly in dis-
cussions on active specific immunization and adoptive T
cell transfer in cancer patients [25]. Our data do not
directly support this assumption. There are only indirect
links between T cell response and Treg infiltration: the
Treg infiltration is higher in patients without systemic
TAA-specific T cell response at a non-significant level, and
Tregs are increased in patients with limited disease, in
whom T cell responses are less frequent. We only begin to
understand the relationships between tumor-infiltrating
Treg, stage of disease, and systemic T cell response against
TAA; and they have to be further investigated.
Our study adds new data to the ongoing discussion on the
role of Tregs in malignant diseases. Our in situ analysis
demonstrates a strong increase of Tregs in CRC compared
to normal colonic mucosa and a predominant Treg pres-
ence in the stroma of CRC. It provides evidence that Treg
infiltration is increased locally in limited stages of CRC.
Furthermore, our data show that Treg infiltration is a
rather dynamic process, in which Treg infiltration at the
primary tumor site increases during early stages of CRC
and decreases in advanced disease. Additionally, our
study underlines the fact that each malignant disease
seems to have its own characteristics concerning the influ-
ence of Treg infiltration on survival. Therefore, it suggests
a precautionary approach during the modulation of the
balanced system of Tregs and CD8 T cells by immuno-
and chemotherapy.
Abbreviations
CRC – colorectal cancer, Treg – regulatory T cell, FOXP3 –
transcription factor forkhead box P3, HPF – high power
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